CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.
Company profile
Ticker
CRSP
Exchange
Website
CEO
Samarth Kulkarni
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
CRISPR Therapeutics, Inc. • TRACR Hematology Ltd • CTX Financing GmbH • CTX Securities Corporation ...
CRSP stock data
Latest filings (excl ownership)
PRE 14A
Preliminary proxy
27 Mar 24
10-K
2023 FY
Annual report
21 Feb 24
8-K
CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
21 Feb 24
8-K
Entry into a Material Definitive Agreement
13 Feb 24
424B5
Prospectus supplement for primary offering
13 Feb 24
8-K
Other Events
13 Feb 24
8-K
Other Events
16 Jan 24
8-K
Departure of Directors or Certain Officers
19 Dec 23
8-K
Other Events
15 Dec 23
8-K
Entry into a Material Definitive Agreement
13 Dec 23
Latest ownership filings
4
JAMES R. KASINGER
22 Mar 24
4
Raju Prasad
22 Mar 24
4
Samarth Kulkarni
22 Mar 24
144
Notice of proposed sale of securities
22 Mar 24
4
Raju Prasad
18 Mar 24
4
Samarth Kulkarni
18 Mar 24
144
Notice of proposed sale of securities
15 Mar 24
4
JAMES R. KASINGER
12 Mar 24
4
Samarth Kulkarni
12 Mar 24
4
Simeon George
27 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 539.60 mm | 539.60 mm | 539.60 mm | 539.60 mm | 539.60 mm | 539.60 mm |
Cash burn (monthly) | (no burn) | (no burn) | 44.14 mm | 35.31 mm | 13.29 mm | 23.14 mm |
Cash used (since last report) | n/a | n/a | 262.69 mm | 210.13 mm | 79.07 mm | 137.70 mm |
Cash remaining | n/a | n/a | 276.90 mm | 329.47 mm | 460.52 mm | 401.90 mm |
Runway (months of cash) | n/a | n/a | 6.3 | 9.3 | 34.7 | 17.4 |
Institutional ownership, Q3 2023
86.2% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 409 |
Opened positions | 46 |
Closed positions | 53 |
Increased positions | 148 |
Reduced positions | 99 |
13F shares | Current |
---|---|
Total value | 2.45 tn |
Total shares | 69.22 mm |
Total puts | 1.40 mm |
Total calls | 1.30 mm |
Total put/call ratio | 1.1 |
Largest owners | Shares | Value |
---|---|---|
ARK Investment Management | 7.16 mm | $325.13 bn |
Capital International Investors | 6.09 mm | $276.22 bn |
VRTX Vertex Pharmaceuticals | 5.38 mm | $353.37 mm |
T. Rowe Price Investment Management | 3.65 mm | $164.62 bn |
CMTDF Sumitomo Mitsui Trust | 3.47 mm | $157.30 bn |
Nikko Asset Management Americas | 3.47 mm | $157.26 bn |
GSK GSK | 3.31 mm | $278.46 mm |
Bayer Global Investments B.V. | 2.95 mm | $154.89 mm |
BLK Blackrock | 2.71 mm | $123.15 bn |
Versant Venture Capital IV | 2.09 mm | $177.93 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
20 Mar 24 | Kasinger James R. | RSU Common Shares | Grant | Acquire A | No | No | 0 | 25,000 | 0.00 | 25,000 |
20 Mar 24 | Kasinger James R. | Stock Option Common Shares | Grant | Acquire A | No | No | 72.94 | 33,333 | 2.43 mm | 33,333 |
20 Mar 24 | Raju Prasad | RSU Common Shares | Grant | Acquire A | No | No | 0 | 25,000 | 0.00 | 25,000 |
20 Mar 24 | Raju Prasad | Stock Option Common Shares | Grant | Acquire A | No | No | 72.94 | 36,168 | 2.64 mm | 36,168 |
20 Mar 24 | Samarth Kulkarni | RSU Common Shares | Grant | Acquire A | No | No | 0 | 78,750 | 0.00 | 78,750 |
20 Mar 24 | Samarth Kulkarni | Stock Option Common Shares | Grant | Acquire A | No | No | 72.94 | 105,000 | 7.66 mm | 105,000 |
15 Mar 24 | Samarth Kulkarni | Common Shares | Sell | Dispose S | No | Yes | 73.0604 | 9,387 | 685.82 k | 208,122 |
15 Mar 24 | Samarth Kulkarni | Common Shares | Sell | Dispose S | No | Yes | 71.9693 | 10,613 | 763.81 k | 217,509 |
15 Mar 24 | Samarth Kulkarni | Common Shares | Option exercise | Acquire M | No | No | 19.12 | 20,000 | 382.40 k | 228,122 |
15 Mar 24 | Samarth Kulkarni | Stock Option Common Shares | Option exercise | Dispose M | No | No | 19.12 | 20,000 | 382.40 k | 19,582 |
News
If You Invested $1000 In This Stock 5 Years Ago, You Would Have $2,000 Today
19 Mar 24
Cathie Wood's Ark Invest Keeps Dumping Coinbase Shares Amid Bitcoin, Crypto Buzz
12 Mar 24
Median Drug Prices For Rare Diseases Hit $300K In 2023, Report Highlights Lack of Clear Rationale Behind Escalating Drug Prices
26 Feb 24
Morgan Stanley Maintains Underweight on CRISPR Therapeutics, Raises Price Target to $48
26 Feb 24
If You Invested $1000 In This Stock 5 Years Ago, You Would Have $2,100 Today
23 Feb 24
Press releases
CRISPR Therapeutics Proposes New Appointment to the Board of Directors
13 Mar 24
CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
21 Feb 24
CRISPR Therapeutics Announces $280 Million Registered Direct Offering
13 Feb 24
European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT)
13 Feb 24
CRISPR Therapeutics Announces U.S. Food and Drug Administration (FDA) Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Transfusion-Dependent Beta Thalassemia
16 Jan 24